Value through InnovationApril 22 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure


Boehringer Ingelheim has a successful 2015 financial year


FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung


Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology


Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy


New Survey: People Living with Asthma Believe it is Controlled, But Persistent Symptoms and Limits to Everyday Activities Tell a Different Story


Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations


The 4WARD Coalition™ Launches to Encourage Shared Decision Making Between AFib Patients and Healthcare Providers


FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray for COPD Health-Related Quality of Life


Propeller Health and Boehringer Ingelheim Announce New Partnership Focused on Improving Adherence and Care Management for People Living with COPD and Asthma

back 1 2 3 4 5 6 7 8 9 10